Combining toripalimab with chemotherapy for advanced gastric cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of neoadjuvant chemoimmunotherapy using toripalimab combined with FLOT chemotherapy in patients with locally advanced gastric and gastroesophageal junction cancer. Participants are divided into two groups, receiving treatment on different days of their chemotherapy cycles, followed by surgical intervention. The study aims to evaluate the pathological complete response and median disease-free survival among the participants. Preliminary results indicate no significant differences in outcomes between the two treatment regimens.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 70 ≥ Age ≥ 18 years regardless of gender
* Gastric adenocarcinoma confirmed by pathology
* no distant metastasis and resectable or potentially resectable evaluated by general surgery experts
* ECOG PS 0-1
* clinical stage T3/4 or N+ by AJCC 8.0
* PD-L1 CPS ≥1 (IHC 22C3 pharm Dx assay (Dako))
* expected lifespan over 3 months
* Adequate organ function: 1) without growth factor and blood component support in the first 2 weeks of enrollment; 2) Cardiac function: no heart disease or coronary heart disease, grade 1-2; 3) liver function: TBIL ≤ 2ULN, AST ≤ 2.5 ULN, alt ≤ 2.5 ULNX 4 Renal function: cr ≤ 1.25ULN, liver function: TBIL ≤ 2ULN, TBIL ≤ 2.5ULN, alt ≤ 2.5ULN, 4)renal function: cr ≤ 1.25ULN.
* blood pressure normal or controlled within the normal range by antihypertensive drugs
* Diabetic patients were treated with hypoglycemic drugs to control fasting blood glucose ≤ 8mmol/L
* Patients with positive hepatitis B surface antigen need to be tested for quantitative detection of hepatitis B DNA virus. HBV DNA should be less than the upper limit of the normal test value for patients with HBV infection.
* no other serious diseases conflicting with this study
* No history of other malignant tumors
* Women of childbearing age must be tested negative for blood pregnancy test within 7 days before enrollment, and subjects of childbearing age must use appropriate contraceptive measures during the trial and within 6 months after the trial
* agreement to participate in this study and signed the informed consent form

Exclusion Criteria:

* Pregnant or lactating women
* Suffered from severe infectious diseases within 4 weeks before entering the group
* Bronchial asthma requires intermittent use of bronchodilators or medical intervention
* Due to the use of immunosuppressants before coexisting diseases and the dosage of immunosuppressants ≥ 10mg/, the oral dose of prednisone lasted for more than 2 weeks
* Clinically obvious cardio-cerebrovascular diseases, including, but not limited to, severe acute myocardial infarction, instability or severe angina pectoris, coronary artery bypass surgery, congestive heart failure, ventricular arrhythmias requiring medical intervention, left ventricular ejection fraction \< 50%, stroke within 6 months
* Allergic to any experimental drug and its excipients, or have a history of severe allergy, or are contraindications to experimental drugs
* Severe mental disorders
* Abnormal coagulation function (PT \> 16s, APTT \> 53s, TT \> 21s Fib \< 1.5g/L), bleeding tendency or undergoing thrombolysis or anticoagulation therapy
* Past or present pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, severe impairment of lung function, etc.
* Unable to swallow research drugs, chronic diarrhea (including but not limited to irritable bowel syndrome, Crohn's disease, ulcerative colitis) and intestinal obstruction affect drug use and absorption
* Have a history of immunodeficiency, including positive for HIV, or suffer from other acquired, congenital immunodeficiency diseases, or have a history of organ transplant
* Other researchers evaluate those who do not meet the criteria for admission

Where it's running

• Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital
  Zhengzhou, Henan, China Recruiting

Study contacts

• Principal investigator: Quanli Gao, M.D — Department of Immunotherapy, Henan Provincial Cancer Hospital
• Study coordinator: Quanli Gao, M.D
• Email: gaoquanli2015@126.com
• Phone: +8637165587483

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Intestinal Low-Dose Radiotherapy plus Immunochemotherapy to Convert Borderline Resectable or Unresectable Esophageal Squamous Cell Carcinoma

  This study tests whether adding a very low dose intestinal radiotherapy with immunochemotherapy can make advanced esophageal squamous cell carcinoma operable for patients who can’t be surgically removed today.

  Recruiting Phase 2 Shantou University Medical College · Shantou, Guangdong · NCT07339488

• Evaluating COVID-19 vaccine effectiveness in lung cancer patients

  This study is testing whether getting a COVID-19 booster shot helps lung cancer patients on treatment avoid severe infections and stay healthier compared to those who don’t get the booster.

  Recruiting Peking Union Medical College Hospital · Beijing · NCT06168032

• Induction chemotherapy with low-dose radiation and cadonilimab for locally advanced nasopharyngeal carcinoma

  This study will try adding low-dose radiation and the immune drug cadonilimab to induction chemotherapy before standard concurrent chemoradiotherapy in adults with newly diagnosed locally advanced nasopharyngeal carcinoma.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong and 2 other locations · NCT05941741

• Comparing two treatment approaches for advanced oral squamous cell carcinoma

  This study is testing whether a new combination treatment for advanced oral cancer can work better than the standard treatment to help patients before surgery.

  Recruiting Phase 2/3 Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT05125055

• TMV vaccine alone or with toripalimab for recurrent head and neck cancer

  This study tests a personalized TMV vaccine, alone and with toripalimab, in adults whose head and neck cancer has returned and is planning salvage surgery.

  Recruiting Phase 1 Metaclipse Therapeutics Corporation · Houston, Texas · NCT07898124

• Toripalimab Plus Cetuximab and Irinotecan for second-line right-sided colon cancer

  This phase II study tests whether a combo of toripalimab, cetuximab, and irinotecan helps adults with second-line, right‑sided, RAS/BRAF wild-type advanced colon cancer.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07896681

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.